Generic Biosimilar Medicines Association

Making Medicines Affordable

  • Home
  • About GBMA
    • Contact us
    • GBMA Members
    • Guiding principles
    • Code of Practice
      • Code Complaint Committee
      • Event Reporting
        • Educational Events
        • Non-Price Benefit Reports
      • Annual Review
        • 2011
        • 2012
        • 2013
        • 2014
        • 2015
        • 2016
        • 2017
        • 2018
      • Lodging a complaint
    • Media Enquiries
    • Our Objectives
    • Links
  • Advocacy
    • Extended Strategic Agreement
    • Generic Medicines Working Group (GMWG)
    • Submissions
  • Generics
    • Facts and Fallacies
    • Key Figures on Generic Medicines
    • What is a Generic Medicine?
    • Bioequivalence Explained
  • Biosimilars
    • GBMA Position on Biosimilars
      • Impact of Biosimilars
      • Switching
      • Pharmacy Substitution
      • Regulation
      • Awareness and Uptake
      • Naming
    • Key Figures on Biosimilars
  • Topics
    • IGBA
    • Price Disclosure
    • Intellectual Property
    • International Trade Agreements
  • News
    • News 2019
    • News 2018
    • News 2017
    • News 2016
    • News 2015
    • News 2014
  • GBMA Education
You are here: Home / Latest news / News 2019 / As focus grows for biosimilars, GBMA welcomes its newest member Celltrion

As focus grows for biosimilars, GBMA welcomes its newest member Celltrion

July 18, 2019 By Admin

18 July 2019

Canberra, ACT

A commitment to drive the uptake of biosimilar medicines in Australia has seen Korean biopharmaceutical company, Celltrion Healthcare, join Australia’s peak body representing generic and biosimilar manufacturers, the Generic and Biosimilar Medicines Association (GBMA).

GBMA Chief Executive Officer, Ms Marnie Peterson, welcomed Celltrion Healthcare as the first member to join the Association’s new ‘Biosimilar Membership’.

“This is further evidence of the role that biosimilar medicines can play in ensuring a sustainable healthcare system for Australian patients, particularly for the Pharmaceutical Benefits Scheme (PBS),” Ms Peterson said.

“Biosimilars provide a real opportunity to help manage the growing costs of new medicines such as biologics.”

“Similar to the opportunity generic medicines provide, there is an enormous potential for biosimilars to significantly reduce the pressure on the PBS while increasing patient access to safe, affordable and life changing medicines,” she said.

Mr Hyoung-Ki Kim, Vice Chairman & CEO at Celltrion Healthcare looks forward to the new partnership with GBMA.

“With the recent establishment of Celltrion Healthcare Australia Pty Ltd. in Sydney, we are excited to be a member of the Generic and Biosimilar Medicines Association (GBMA).”

“At Celltrion Healthcare, our aim is to provide the best possible treatment options for patients and healthcare providers, and by connecting with the GBMA, we look forward to engaging positively to support the uptake of biosimilar medicines in Australia as a way to alleviate pressure on its national health system.”, Mr Kim said.

The GBMA’s Biosimilar Membership looks to support the varying nature of manufacturing portfolios currently seen in market, which highlights the need for a dedicated membership structure for biosimilar manufacturers without a generic portfolio.

“The addition of our newest member underscores the evolution of GBMA’s role within the Australian healthcare framework and we welcome Celltrion Healthcare to the GBMA, joining us on the biosimilar journey in Australia.”, said Ms Peterson.

–ENDS–

ABOUT GBMA
The GBMA is the national association representing companies that manufacture, supply and export generic and biosimilar medicines. GBMA represents all major generic medicine suppliers in Australia, accounting for more than 90% of all generic medicines dispensed in Australia. Members of GBMA ensure all Australians are offered high quality generic and biosimilar medicines, which provide affordable health outcomes that benefit all Australians. Members of GBMA take seriously their role in the responsible provision of affordable medicines in Australia, as stipulated in the National Medicines Policy. The generic and biosimilar medicines sector is a high value-add sector delivering significant health and economic benefits to the Australian public. The availability of generic medicines in this country helps to deliver:

– Timely access to affordable medicines;
– Substantial savings to the PBS;
– Thousands of highly skilled jobs; and
– Domestic manufacturing and annual exports of around $300 million.

For more information, please contact the GBMA – admin@gbma.com.au or visit www.gbma.com.au

–ENDS–

Filed Under: News 2019

Our Members

Juno
Juno
Sandoz logo
Sandoz logo
Mylan
Mylan
Arrow logo
Arrow logo
apotex
apotex
Celltrion Healthcare
Celltrion Healthcare
Fresnius Kabi
Fresnius Kabi
Fresnius Kabi
generic_partners
generic_partners
southern_cross
southern_cross
commercial_eyes
commercial_eyes
iqvia
iqvia
sinapse
sinapse

Generic Medicines: The Facts

Generic Medicines Facts

Generic medicines are quality medicines at affordable prices. Ask your doctor to prescribe a generic medicine, or ask for a generic medicine next time you take your prescription to the pharmacy. … More…

The promise of Biosimilars

Biosimilars

https://youtu.be/sBDur7xa084   Biosimilars provide a unique opportunity to help manage the growing costs of biological medicines on the PBS. They offer therapeutically equivalent and … More…

GBMA welcomes Fresenius Kabi Australia

October 4, 2019

4 October 2019 Canberra, ACT Canberra: Australia’s peak body representing generic and biosimilar manufacturers, the Generic and … More...

Federal Health Minister, Greg Hunt MP encourages healthcare sector to embrace biosimilar medicines.

October 2, 2019

2 October 2019 Doctors, pharmacists, medical researchers, and hospital leaders attend 'Your … More...

GBMA welcomes new appointment to the Board

September 30, 2019

30 September 2019 Canberra, ACT The nation’s peak body for generic and biosimilar … More…

© 2019 Generic Medicines Industry Association Pty Ltd | Site Map | Contact Us